Correction: Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics

Xiaoting Lin^{1

2

3

4}, Peng Liu^{1

2

3

4}, Guoyan Qi^{1

2

3

4}

Affiliations

¹ Department of Oncology, Hebei Medical University, Shijiazhuang, Hebei, China.
² Treatment Center of Myasthenia Gravis, People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
³ Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, Hebei, China.
⁴ Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, Hebei, China.

Published Erratum

Xiaoting Lin et al. Front Immunol. 2025.

. 2025 Jul 9:16:1650718.

doi: 10.3389/fimmu.2025.1650718. eCollection 2025.

Xiaoting Lin^{1

2

3

4}, Peng Liu^{1

2

3

4}, Guoyan Qi^{1

2

3

4}

¹ Department of Oncology, Hebei Medical University, Shijiazhuang, Hebei, China.
² Treatment Center of Myasthenia Gravis, People's Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
³ Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, Hebei, China.
⁴ Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, Hebei, China.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2025.1580219.].

Keywords: biomarkers; myasthenia gravis; prognostic; proteomics; thymoma.

Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics.
Lin X, Liu P, Qi G. Lin X, et al. Front Immunol. 2025 Jun 17;16:1580219. doi: 10.3389/fimmu.2025.1580219. eCollection 2025. Front Immunol. 2025. PMID: 40599774 Free PMC article.